Date: Jun 09, 2015 Source: PR Newswire (
click here to go to the source)
MILFORD, Mass., June 9, 2015 /PRNewswire/ -- SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced the formation of a new business unit focused on the development of technologies and products to help enable the safe and effective expansion of precision medicine-driven diagnostics. The Molecular and Precision Medicine Business Unit will be tasked with developing innovative solutions to support the accurate and precise use of these advanced diagnostic platforms such as next generation sequencing (NGS) and digital PCR (dPCR). SeraCare also announced today the hiring of Trevor Brown as the Vice President, Precision Medicine to lead the new business unit.
"For over 30 years, SeraCare has supported diagnostic test developers and clinical testing laboratories with tools to improve the quality and safety of their diagnostic tests. Given this experience, we are in a unique position to help our customers as they transition to more data-intensive diagnostic methods and embrace new technologies such as next generation sequencing and digital PCR," said Charlie Mamrak, CEO of SeraCare. "Precision medicine will drive the future growth of the diagnostics industry and I am excited to welcome Trevor to help us realize this vision. He brings extensive diagnostic industry experience as well as solid scientific strategies for advancing our tools along the path to precision medicine."
Trevor Brown comes to SeraCare from Luminex where he was the Director of Global Clinical Diagnostics Strategy. In this position, he led the development of the long-term menu strategy for molecular diagnostics platforms and developed go-to-market strategies for precision medicine and laboratory-developed testing solutions. Prior to this position, Trevor held several program leadership roles in the research immunology business at BD Biosciences.
About SeraCare Life Sciences, Inc.
SeraCare enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents. For more information, please visit www.seracare.com and follow SeraCare on Twitter (@SeraCare).
CONTACT:
Kim Anderson
(508) 244-6429
kanderson@seracare.com
SOURCE SeraCare Life Science
